- American City Business Journals•19 days ago
The former CEO of Ariad Pharmaceuticals Inc., who spent the last year shaping up the Cambridge-based drug company for its $5.2 acquisition earlier this year, was just named to the board of a new biotech last week. There, as the newest board member of New Jersey-based The Medicines Company, Paris Panayiotopoulos joins a familiar face: Alex Denner, former chairman of Ariad (ARIA). The founder of hedge fund Sarissa Capital, an activist investor believed to have played a big role in orchestrating the sale of that company, was named to that same 11-member board just over a year ago.
- Investopedia•26 days ago
Amgen aims to expand the use of Blincyto for more indications of acute lymphoblastic leukemia
- Market Realist•2 months ago
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.
ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance
ARIAD Pharmaceuticals, Inc. (ARIA)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|